Epidemic Benefited The Vaccine Manufacturers

Raising hopes for normalization, coronavirus vaccines have brought billions of dollars to manufacturing companies.

The epidemic benefited the vaccine manufacturers. During the coronavirus outbreak, many countries did not avoid spending on millions of doses of vaccine to be used in widespread vaccination programs. The European Union ordered a total of 780 million doses of coronavirus vaccine produced by BioNTech and Pfizer, including 300 million doses, the USA 200 million doses, Covid-19 Vaccines Global Access Program (COVAX) 40 million doses. According to the news in The Guardian, Pfizer, which shares costs and profits equally with BioNTech, expects sales of $ 15 billion in 2021, based on current agreements. As companies announced that they have the capacity to supply 2 billion doses in 2021, total sales are estimated to reach up to $ 30 billion. Known as a more established company compared to others, Pfizer's shares have increased by 1.8 percent in the last 12 months, while BioNTech shares have increased by 156 percent. Moderna from the USA is following Pfizer-BioNTech with the agreements it has made. The company received orders from the European Union for a total of 460 million doses, including 310 million in 2021 and 150 million in 2022. However, it was learned that he received an order of 300 million doses from the USA and 50 million doses from Japan. In the statement made by Moderna, it was predicted that a sale of $ 18.4 billion could be made in 2021. The 11-year-old company's shares increased by 372 percent in 12 months. Janssen, a subsidiary of Johnson&Johnson in Belgium, headquartered in the USA, received 52 million doses of orders from the USA and England with the single-dose coronavirus vaccine it produced. However, the company announced that it has received 400 million doses of vaccine orders from the EU and 500 million doses of vaccine orders from COVAX by 2022. Stating that it has the capacity to deliver 1 billion doses of coronavirus vaccine by the end of 2021, the company's shares have increased by 7.7 percent in the last 12 months. It is estimated that Janssen will make sales of $ 10 billion in 2021. The British-Swedish pharmaceutical company AstraZeneca also received an order of 400 million doses from the EU, 300 million doses from the USA, 120 million doses from Japan, and 100 million doses from the UK. The company, which is expected to sell $ 3 billion in 2021, set a low fee of $ 10 for two doses of vaccine. The company's shares, on the other hand, lost value by 8.6 percent in 12 months, unlike other companies. The vaccine developed by the Chinese pharmaceutical company Sinovac was approved and started to be used in countries such as Turkey, Brazil, Chile, Singapore, Malaysia and the Philippines. Planning to produce 10 million doses of vaccine, the company's sales are not known clearly. Sinovac's shares have also lost 21.6 percent in the last 12 months. While the coronavirus vaccine belonging to the Russian Gamaleya Institute, the vaccines produced by the US Novavax and German CureVac pharmaceutical companies received hundreds of millions of doses of vaccine orders, information on the total sales of the companies could not be obtained. Novavax has become the most valuable company among vaccine manufacturers, with an increase of 1128 percent in the last 12 months.